Seres Therapeutics (MCRB) Debt Ratio (2014 - 2024)

Seres Therapeutics (MCRB) posted Debt Ratio of 0.32 for Q2 2024, up 6.57% sequentially from 0.3 in Q1 2024, and up 28.51% YoY from 0.25 in Q3 2023.

Seres Therapeutics (MCRB) Debt Ratio (2014 - 2024) Analysis & Trends

Seres Therapeutics has reported Debt Ratio for 11 years, with the latest figure at 0.32 in Q2 2024.

Quarterly Debt Ratio rose 28.51% year-over-year to 0.32 in Q2 2024, while the trailing twelve-month figure through Jun 2024 was 0.32 (up 28.51% YoY) and the FY2023 annual result came in at 0.28, up 95.22% from the prior year.
Debt Ratio climbed to 0.32 in Q2 2024 per MCRB's latest filing, from 0.3 in the prior quarter.
Over five years, Debt Ratio peaked at 0.32 in Q2 2024 and troughed at 0.04 in Q3 2021.
A 5-year average of 0.17 and a median of 0.17 in 2022 frame the typical range for Debt Ratio.
The sharpest annual moves came in 2021 and 2022: Debt Ratio sank 71.41% in 2021, then surged 300.97% in 2022.
Over 5 years, Debt Ratio stood at 0.07 in 2020, then dropped by 3.34% to 0.07 in 2021, then soared by 108.87% to 0.15 in 2022, then jumped by 95.22% to 0.28 in 2023, then gained by 12.5% to 0.32 in 2024.
According to Business Quant data, Debt Ratio over the past three periods registered 0.32, 0.3, and 0.28 for Q2 2024, Q1 2024, and Q4 2023 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	138.71 Bn	130.86 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.60 Bn	77.60 Bn	3.93 Bn	0.05
3	Argenx Se	64.82 Bn	59.63 Bn	1.37 Bn	-
4	Moderna	57.92 Bn	52.79 Bn	52.00 Mn	0.05
5	BeOne Medicines	41.88 Bn	36.78 Bn	1.53 Bn	0.12
6	Alnylam Pharmaceuticals	31.46 Bn	28.15 Bn	992.69 Mn	-
7	BioNTech SE	27.96 Bn	9.57 Bn	668.28 Mn	0.03
8	Insmed	27.35 Bn	26.19 Bn	358.27 Mn	0.26
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	0.47
10	Seres Therapeutics	43.87 Mn	43.87 Mn	-	-

Download Data